by telrheum | Mar 31, 2024 | Biologic Therapy, Magnetic Resonance Imaging, Psoriatic Arthritis
The article discusses a study on how tumor necrosis factor-alpha (TNFα) inhibition, a treatment for psoriatic arthritis (PsA), affects pain processing in the brain, using functional magnetic resonance imaging (fMRI). The study included 6 PsA patients, some new to...
by telrheum | Mar 31, 2024 | Psoriasis, Psoriatic Arthritis, Spondyloarthritis
Hemay005 is an experimental drug being tested for its ability to treat chronic inflammatory diseases like psoriasis by inhibiting a specific enzyme, PDE4, which plays a key role in the inflammation process. The drug aims to reduce the activity of T lymphocytes and...
by telrheum | Mar 23, 2024 | Biologic Therapy, Psoriatic Arthritis, Rheumatic Drugs, Rheumatoid Arthritis, Spondyloarthritis, Viral Infections
Paxlovid’s Effectiveness Paxlovid, comprised of nirmatrelvir and ritonavir, has been recognized for its effectiveness in treating COVID-19. It works by inhibiting the protease of SARS-CoV-2, preventing the virus from replicating. Studies indicate that it...
by telrheum | Mar 18, 2024 | Rheumatic Drugs, Biologic Therapy, Psoriatic Arthritis, Rheumatoid Arthritis, Spondyloarthritis
Arthritis is a common condition characterized by inflammation of one or more joints, leading to pain, swelling, stiffness, and reduced range of motion. It affects millions of people worldwide and can significantly impact quality of life. There are several types of...
by telrheum | Mar 16, 2024 | Biologic Therapy, Psoriatic Arthritis, Rheumatic Drugs, Spondyloarthritis
Bimekizumab, a novel biologic therapy, is showing promising results in the treatment of psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis (nr-axSpA, M46.80). This medication belongs to a class of drugs known as monoclonal...
